- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02197208
A RCT Comparing Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in FET
A Randomized Controlled Comparison of Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in Frozen-thawed Embryos Transfer
연구 개요
상세 설명
Embryo cryopreservation is essential nowadays. It allows the usage of surplus good quality embryos in frozen-thawed embryo transfer (FET) cycles which avoids embryo wastage and facilitates the adoption of transferring a small number of embryos in the fresh stimulation cycle so as to reduce the risk of multiple pregnancy during in vitro fertilization (IVF) treatment. Elective cryopreservation of all fresh embryos is also required in special circumstances where fresh transfer is undesirable, for example in cases where a high risk of ovarian hyperstimulation syndrome is anticipated. Fresh transfer is not advisable when serum progesterone level is elevated or hydrosalpinx is detected during ovarian stimulation.
The availability of FETs would increase the likelihood of successful pregnancy from a single superovulation and oocyte retrieval cycle. It has been estimated that in modern IVF programmes which incorporates embryo cryopreservation, up to 42% of all conceptions could be derived from FET (Borini et al, 2008).
Although the pregnancy rate in FET is comparable with stimulated IVF cycles, the optimal regimen to prepare the endometrium for implantation is not yet well proven. By a recent Cochrane review, there is no evidence to prove the use of one regimen in preference to another (Ghobara T 2008).
Natural cycles (NC) are considered the best regimen as it is physiological, where natural conception occurs in. However, there are two most commonly employed methods to time the ovulation in natural cycles. One is to use ultrasound (USG) to monitor the follicular growth and endometrial thickness, with the use of human chorionic gonadotrophin (hCG) to trigger ovulation in the presence of a dominant follicle around 17-18mm in diameter. Another is to monitor the blood hormonal concentration to detect the luteinising hormone (LH) surge associated with natural ovulation. There is scarce information in this area as only one randomized controlled trial compared these two approaches. The authors aimed to recruit 240 subjects, but the study was prematurely terminated as significant results were resulted in the first interim analysis when the sample size reached 124. The ongoing pregnancy rate was 31.1% in the group with spontaneous LH surge and 14.3% in the hCG-induced group (Fatemi et al., 2010).
The use of natural LH surge and hCG trigger in intrauterine insemination was compared too. A meta-analysis revealed a significantly higher clinical pregnancy rate in IUI cycles with natural LH surge than that with hCG trigger. However, the data from randomized controlled trial showed no significant difference. Also the data were contradictory when the analysis confined to a specific indication of subfertility (Kosmas et al., 2007). A cochrane review in 2012 also suggested there was no evidence to advise that any regimen was better than another (Cantineau et al., 2012).
This randomized controlled trial aims to compare the ongoing pregnancy rate of FET in spontaneous NC and hCG-induced NC. The hypothesis of this trial is that the ongoing pregnancy rate of FET is similar for spontaneous NC and hCG-induced NC. The advantage of hCG-induced NC is likely a reduction in the duration of monitoring for timing FET when compared with spontaneous NC.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age of women <43 years
- Regular menstrual cycles ranging from 21-35 days with not more than 4 days variation between cycles
- Undergoing FET in natural cycles
- Normal uterine cavity as shown on saline sonogram performed before the IVF cycle or normal uterine cavity shown on pelvic scanning during the stimulated IVF cycle
- Endometrial thickness >=8mm in both stimulated IVF and FET cycles
Exclusion Criteria:
- >3 previous IVF cycles
- >6 embryos replaced without pregnancy
- Irregular menstrual cycles
- Subjects requiring clomid-induced cycles and hormonal replacement (HRT) cycles
- History of previous FET cycles within the study period
- Blastocyst transfer
- Preimplantation genetic diagnosis treatment
- Use of donor oocytes
- Presence of hydrosalpinx not corrected surgically prior to FET
- Recurrent miscarriage
- Serum progesterone level on the day of LH surge or day of hCG >5 nmol/L or 1.5 pg/L (these patients will be retrospectively excluded)
- Refusal to join the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Spontaneous NC
Timing by the onset of LH surge as shown daily blood monitoring of serum estradiol and LH levels
|
ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter.
Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter.
5 ml of blood would be taken daily.
LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L.
Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness.
The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
|
|
실험적: hCG induced NC
Timing by giving hCG when the dominant follicle reaches >=17mm in diameter on ultrasound monitoring
|
ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days.
hCG, 5,000-10,000 IU will be given when the leading follicle is >/= 17 mm and the endometrium measures >/=8 mm.
Serum E2, LH and progesterone levels will be measured on the day of hCG.
Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
ongoing pregnancy rate
기간: 12 weeks after embryos transfer
|
the ongoing pregnancy rate which is defined as the number of viable pregnancies beyond 10-12 weeks gestation per transfer cycle
|
12 weeks after embryos transfer
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Days of monitoring for timing FET
기간: 4 weeks after last menstrual period
|
The number of days needed for the monitoring for the timing of FET
|
4 weeks after last menstrual period
|
|
Endometrial thickness on day of hCG or the next day after LH surge
기간: 2-3 weeks after LMP
|
The measurement of the endometrial thickness on the day of hCG or the next day after LH surge
|
2-3 weeks after LMP
|
|
Implantation rate
기간: 4-6 weeks after embryo transfer
|
Implantation rate: number of gestational sacs per number of embryos transferred
|
4-6 weeks after embryo transfer
|
|
pregnancy rate
기간: 2-4 weeks after embryo transfer
|
number of positive pregnancy rate per transfer
|
2-4 weeks after embryo transfer
|
|
Clinical pregnancy rate
기간: 6-8 weeks after embryo transfer
|
Number of pregnancy with positive fetal pulsation on scanning at 6 weeks of gestation.
|
6-8 weeks after embryo transfer
|
|
Miscarriage rate
기간: 20 weeks after embryo transfer
|
rate of pregnancy loss <20 weeks per transfer cycles
|
20 weeks after embryo transfer
|
|
Multiple pregnancy rate
기간: 20 weeks after embryo transfer
|
The rate of multiple pregnancy after ET
|
20 weeks after embryo transfer
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- HKU-VL-NChCGFET
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
임신에 대한 임상 시험
-
The Nazareth Hospital, Israel완전한Streptococcus B Carrier State Complicating Pregnancy이스라엘
초음파에 대한 임상 시험
-
Fujian Medical University아직 모집하지 않음림프 전이 | 갑상선 신생물 | 갑상선 유두암 | Ret Proto-Oncogene 돌연변이중국
-
Tobias TodsenAarhus University Hospital; Hillerod Hospital, Denmark; Køge Hospital, Denmark모병
-
Academisch Medisch Centrum - Universiteit van Amsterdam...완전한
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...모병
-
Ajou University School of Medicine종료됨